Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of FPA008 in
PVNS/dt-TGCT patients. Patients will be enrolled into either Phase 1 (dose escalation) or
Phase 2 (dose expansion) of the study, but not both.